DLA Piper has advised Perimed in connection with the strategic investment from Serendipity Partners

DLA Piper has advised Perimed AB ("Perimed"), a Swedish MedTech company and world leader in instruments for advanced vascular diagnostics, in connection with the strategic investment from Serendipity Partners, a leading Nordic healthcare growth investor. The strategic investment will fuel Perimed’s expansion plans, particularly in the United States.

Read the press release by Perimed here.

DLA Piper's team consisted primarily of Mikael Moreira, Erik Rosberg and Gustav Säde.